Table 2 RE-AIM elements and corresponding measures

Reach:

proportion and representativeness of individuals who participate in an intervention

1) Characteristics of MASLD patients who are referred to weight loss in a given PACT compared with characteristics of all MASLD patients in a given PACT*

2) Characteristics of MASLD patients who are referred to hepatology in a given PACT compared with characteristics of all MASLD patients in a given PACT*

3) Differences between the intervention and control groups in the relationship between patient characteristics and each primary and secondary outcome at 6 months (see Effectiveness)

Effectiveness: impact of an intervention on important outcomes

1) Differences in the proportions of patients with MASLD diagnosis and risk stratification between intervention and control groups*

2) Differences in the proportions of patients with MASLD who are referred to a weight loss program within 6 months between intervention and control groups *

3) Differences in the proportions of patients with advanced MASLD who are referred to hepatology within 6 months between intervention and control groups*

4) Differences in the proportion of patients with MASLD who are referred to a weight loss program and start the program within 6 months between intervention and control groups*

5) Differences in the proportion of patients with advanced MASLD referred to hepatology and are seen in a hepatology clinic within 6 months between intervention and control groups*

Adoption:

proportion and representativeness of individuals who deliver the intervention

1) Characteristics of PACTs participating in the study (make up of clinicians, number of clinicians in PACT) and differences between intervention and control groups in the relationship between PACT characteristics and each outcome at 6 months*

2) Differences among PACTs in frequency of referrals to weight loss and hepatology**

3) Barriers and facilitators to referral to weight loss and hepatology**

Implementation: fidelity to elements of intervention

1) Fidelity to MCCP intervention in terms of education/referral patterns and the relationship between degree of fidelity and each outcome at 6 months (based on documentation of checklist in CPRS)*

2) Adaptations of MCCP delivery by PACT members**

3) Time required to deliver MCCP as reported in interviews**

4) Patient experiences with PACT and providers using MCCP**

Maintenance:

extent to which intervention effects are sustained 6 or more months

(Examination of outcomes at 12 months)

1) Differences in the proportion of patients with MASLD who are NEWLY referred to weight loss program (within 6–12 months) between intervention and control groups*

2) Differences in the proportions of patients with advanced MASLD who are NEWLY referred to hepatology (6–12 months) between intervention and control groups*

3) Differences in the proportion of patients with MASLD who are referred to a weight loss program who actually start the program within 12 months between intervention and control groups

4) Differences in the proportion of patients with advanced MASLD referred to hepatology who actually see a hepatology clinic within 12 months between intervention and control groups